GleamWall
中文EN

NAUT Nautilus Biotechnology, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1808805 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.7%
TTM EPS YoY8.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-41.0%
ROA-33.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets21.7%
Debt / equity0.00x
Current ratio9.25x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-3.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$41.11M$50.48M
SG&A expense$25.73M$31.00M
Income tax$0$0
Net income-$59.00M-$70.78M
EPS (basic)-0.47-0.56
EPS (diluted)-0.47-0.56
Weighted avg. shares (diluted)126.26M125.43M
Balance sheet
Cash & equivalents$12.39M$28.65M
Short-term investments$91.02M$102.25M
Current assets$105.96M$132.83M
PP&E, net$3.46M$4.08M
Total assets$191.11M$242.74M
Current liabilities$7.95M$7.63M
Total liabilities$34.14M$34.01M
Shareholders' equity$156.97M$208.73M
Shares outstanding126.47M126.11M
Cash flow statement
Operating cash flow-$50.70M-$59.15M
Capital expenditure$1.28M$2.12M
Free cash flow-$51.97M-$61.27M
Investing cash flow$35.22M$66.25M
Financing cash flow$214,000$1.14M
Depreciation & amortization$1.70M$2.00M
Stock-based compensation$6.84M$12.70M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.